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Summary
Primary cilia are implicated in the pathogenesis of
autosomal-dominant polycystic kidney disease (ADPKD),
which results from defects in polycystin-1 (PC1), but
the function of PC1 remains poorly understood. Here,
we show that PC1 undergoes proteolytic cleavage that
results in nuclear translocation of its cytoplasmic tail.
The PC1 tail interacts with the transcription factor
STAT6 and the coactivator P100, and it stimulates
STAT6-dependent gene expression. Under normal
conditions, STAT6 localizes to primary cilia of renal
epithelial cells. Cessation of apical fluid flow results
in nuclear translocation of STAT6. Cyst-lining cells in
ADPKD exhibit elevated levels of nuclear STAT6,
P100, and the PC1 tail. Exogenous expression of the
human PC1 tail results in renal cyst formation in zebra-
fish embryos. These results identify a novel mecha-
nism of cilia function in the transduction of a mechan-
ical signal to changes of gene expression involving
PC1 and show that this pathway is inappropriately ac-
tivated in ADPKD.
Introduction
Autosomal-dominant polycystic kidney disease (ADPKD)
is one of the most common monogenic inherited human
diseases (Igarashi and Somlo, 2002; Sutters and Ger-
mino, 2003; Torres and Harris, 2003; Wilson, 2004). Dur-
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7 These authors contributed equally to this work.ing disease progression, renal epithelial cells proliferate
to form fluid-filled cysts that eventually replace most of
the normal renal tissue, resulting in renal failure in 50%
of the patients by age 50. Currently, no treatment exists
to prevent or slow cyst formation, and most ADPKD pa-
tients require renal transplantation or life-long hemodial-
ysis for survival. Mutations in either of two genes, PKD1
and PKD2, are the underlying cause of ADPKD, with
PKD1 mutations accounting for over 85% of the cases.
The function of the PKD1 gene product, PC1, is poorly
understood. PC1 is a large, integral membrane protein
with putative extracytoplasmic ligand binding domains,
but no physiological ligand has clearly been identified to
date. The C-terminal cytoplasmic tail of PC1 has been
implicated in signal transduction pathways, including
the wnt pathway (Kim et al., 1999b), a pathway leading
to AP-1 transcription factor activation (Arnould et al.,
1998; Chauvet et al., 2004; Le et al., 2004; Parnell et al.,
2002), G protein signaling (Kim et al., 1999a; Parnell
et al., 1998), calcium signaling (Nauli et al., 2003; Van-
dorpe et al., 2001; Xu et al., 2003), and activation of
STAT1 (Bhunia et al., 2002). However, it is unknown
whether these proposed signaling pathways are altered
in ADPKD and if any of them may relate to the altered
growth and transport phenotypes of cystic epithelial
cells. In order to devise a strategy for therapeutic inter-
vention, it will be critical to identify the function of PC1
that—if defective—leads to renal cystogenesis.
Primary cilia of renal epithelial cells are nonmotile ex-
tensions of the apical plasma membranes. Recent evi-
dence suggests that primary cilia in the kidney function
as mechanosensors that are sensitive to lumenal fluid
flow (Praetorius and Spring, 2001, 2003). Recent results
also suggest that PC1 may be involved in mechanosen-
sation (Delmas, 2004; Nauli and Zhou, 2004) because re-
nal epithelial cells derived from PC1 null animals fail to
respond to flow-mediated bending of their cilia with
an elevation of intracellular calcium (Nauli et al., 2003).
PC1 has been detected on primary cilia, and in other cel-
lular locations, but the mechanism of its possible role in
mechanotransduction remains unclear (Delmas, 2004).
Nevertheless, a link between cilia function and PKD ap-
pears very likely because defects in a number of cilia
proteins can lead to renal cystic diseases in humans
and in animal models (Delmas, 2004; Guay-Woodford,
2003; Zhang et al., 2004). Recently, it was shown that
PC1 can undergo proteolysis, which appears to be reg-
ulated by lumenal fluid flow (Chauvet et al., 2004). This
leads to the generation of a C-terminal fragment that
can be detected in nuclei and was reported to play a
role in the regulation of the AP-1 pathway (Chauvet et al.,
2004) that had previously been implicated as a down-
stream effector of PC1 (Arnould et al., 1998; Le et al.,
2004; Parnell et al., 2002).
We report here the identification of a novel, to our
knowledge, signaling pathway that transduces a me-
chanical signal from primary cilia to changes in gene
expression. We found that PC1 undergoes proteolytic
cleavage of its cytoplasmic tail, followed by nuclear
translocation, and we have identified the transcriptional
Developmental Cell
58Figure 1. The Cytoplasmic Tail of PC1 Tar-
gets to the Nucleus
(A) Expression constructs used in this study.
Residue numbers refer to human PC1. Mem-
brane-anchored constructs contain the ex-
tracytoplasmic domain and signal peptide
(SP) of CD16 and the transmembrane domain
of CD7. Epitope tags are: myc (gray circles),
His6 (white circles), and FLAG (black circle).
(B) MDCK cells stably transfected for FLS-
PC1 were cultured for 16 hr in the absence
or presence of 50 ng/ml DOX and 10 mM
ALLN. FLS-PC1 was detected in total cell ly-
sates by Western blot with antibodies against
the C-terminal half of the PC1 tail (aCT) or the
full-length PC1 tail (aFL). Treatment with
ALLN results in significantly elevated levels
of FLS-PC1.
(C–E) MDCK cells stably transfected for FLS-
PC1 or CTM-PC1 (shown in [F]) were cultured
for 16 hr in the absence or presence of 50 ng/
ml DOX and 10 mM ALLN. FLS-PC1 is de-
tected by immunofluorescence with an anti-
myc epitope tag antibody.
(F) The untagged CTM-PC1 serves as an ad-
ditional negative control. The scale bar is 10
mm.
(G–K) Immunohistochemical detection of the
PC1 tail in (G and H) normal human kidney
or (I–K) ADPKD kidney with (G and I) aCT or
(J) aFL antibodies. Histological counterstain-
ing was omitted. The arrowheads highlight
nuclear signals. (H) and (K) show negative
controls with the omission of the primary an-
tibody. For comparison, the immunohisto-
chemistry was carried out side by side, and
images were acquired under identical condi-
tions. The scale bar is 20 mm.machinery that interacts with the PC1 tail and mediates
PC1-regulated gene expression. We show that the PC1
tail binds to the sequence-specific transcription factor
STAT6 and the coactivator P100, and that it stimulates
STAT6-dependent transcription. STAT6 localizes to pri-
mary cilia under normal conditions but undergoes nu-
clear translocation in response to the cessation of apical
fluid flow. The PC1/STAT6/P100 pathway is significantly
upregulated in cyst-lining epithelial cells in human
ADPKD, which suggests its involvement in cellular
changes that bring about renal cystogenesis. These re-
sults identify a signaling pathway that sheds light on the
function of primary cilia and may be a promising target
for strategies for therapeutic intervention for ADPKD.Results
The Cytoplasmic Tail of PC1 Targets to the Nucleus
and Is Overexpressed in ADPKD
We initially made the following observation when ex-
pressing the C-terminal cytoplasmic tail of PC1 (con-
struct FLS-PC1 in Figure 1A) in the MDCK renal epithelial
cell line by stable transfection by using a doxycycline
(DOX)-regulatable promotor. DOX induction resulted in
very low expression levels in all investigated clones
(Figure 1B). Treatment with the proteasome inhibitor
ALLN resulted in significantly elevated expression lev-
els, suggesting that FLS-PC1 is subject to rapid protea-
somal degradation. Surprisingly, FLS-PC1 localized
Polycystin-1/STAT6/P100 Signaling Pathway
59Figure 2. The C-Terminal Half of the PC1 Tail
Is Cleaved, Is Released from the Membrane,
and Targets to the Nucleus
(A and B) As indicated, COS-7 cells were tran-
siently transfected for C-terminally FLAG-
tagged PC1. After treatment for 16 hr in the
absence or presence of 10 mM ALLN, cells
were lysed and PC1 was immunoprecipitated
with the aFL antibody. Immunoprecipitates
were separated on a (A) 4% or (B) 15%
SDS-PAGE gel and were probed with the
aCT antibody in (A). Note the full-length PC1
(arrow in [A]) and the expected w130 kDa
product of cleavage at the GPS domain (ar-
rowhead in [A]). The arrow in (B) indicates
a w17 kDa cleavage product. The asterisk
in (B) indicates nonspecific bands including
IgG heavy and light chains.
(C) MDCK cells stably transfected for FLM-
PC1 were treated for 16 hr with DOX and/or
10 mM ALLN. Cells were fractionated into nu-
clear, total membrane, and cytosolic frac-
tions by differential centrifugation. The frac-
tions were probed by Western blot with
aCT. An w14 kDa cleavage product is pres-
ent in fractions of ALLN-treated cells (arrow).
The asterisk indicates a nonspecific band.
(D) To control for the purity of fractions in (C),
the enrichment of nuclear (lamin), membrane
(GM130), and cytoplasmic (14-3-3) markers
was tested by Western blot.
(E) MDCK cells were transiently transfected
for the indicated PC1 constructs and were
immunostained with the aFL antibody (green).
Nuclei were stained with DAPI (blue). As indi-
cated, cells were treated with leptomycin B
(10 ng/ml) for 3 hr. The scale bars are 10 mm.preferentially to the nucleoplasm (Figure 1E), suggesting
that nuclear targeting of the PC1 tail may have functional
significance.
To test whether the cytoplasmic tail of PC1 may also
undergo nuclear targeting in vivo, we utilized a poly-
clonal antibody (termed aFL) against the full-length tail
(equivalent to FLS-PC1) and another (termed aCT)
against the C-terminal half of the tail (equivalent to
CTS-PC1). Immunohistochemistry of normal human kid-
ney with these two antibodies revealed a weak, but re-
producible, nuclear signal (Figure 1G). Cyst-lining epi-
thelial cells in renal specimens from ADPKD patients
exhibited highly elevated nuclear and cytoplasmic sig-
nals (Figures 1I and 1J). These immunosignals were vari-
able between patients and also from cyst to cyst within
the same specimen. Whereas some cysts exhibited no
detectable signal, the majority were strongly stained.
The C-Terminal Half of the PC1 Tail Is Cleaved
and Released from the Membrane
Since PC1 is an integral membrane protein, the finding
of nuclear localization suggests that the cytoplasmic
tail would have to be released from the rest of the protein
by proteolysis prior to nuclear translocation. PC1 can
undergo proteolysis at a conserved GPS domain in the
N-terminal extracytoplasmic domain (Qian et al., 2002),
which generates an w130 kDa C-terminal fragment
that is comprised of all transmembrane domains and
the cytoplasmic tail. To test whether an additional cleav-age event may release the tail from the membrane, we
expressed full-length, C-terminally FLAG-tagged PC1
in COS-7 cells. As shown in Figure 2A, full-length PC1
(arrow) can be detected along with the anticipated prod-
uct of the cleavage at the GPS domain (arrowhead). Fur-
thermore, a small C-terminal fragment of w17 kDa can
be detected in the presence, but not the absence, of
ALLN (Figure 2B, arrow). Since this fragment is detect-
able with the aCT antibody as well as an antibody
against the C-terminal FLAG epitope (data not shown),
it must consist of the extreme C terminus of PC1. This re-
sult indicates that PC1 not only undergoes cleavage at
the GPS domain but that an additional cleavage event
can lead to the release of the C-terminal half of the cyto-
plasmic tail. Whereas the 130 kDa fragment is relatively
stable, the 17 kDa fragment appears to undergo rapid
proteasomal degradation.
Next, we used MDCK cells that stably express a con-
struct in which the PC1 tail is membrane anchored by fu-
sion to the extracytoplasmic domain of CD16 and the
transmembrane domain of CD7 (FLM-PC1, Figure 1A).
This leads to the expression of the fusion protein of
the expected size of w75 kDa (data not shown). Treat-
ment with ALLN results in the accumulation of a small
fragment ofw14 kDa that reacts with the aCT antibody
(Figure 2C, arrow). This fragment can be identified in nu-
clear and membrane fractions. We estimate that the
w14 kDa fragment that is generated from the FLM-
PC1 fusion protein is equivalent to the w17 kDa
Developmental Cell
60Figure 3. The PC1 Tail Interacts with P100
(A) Sequencing of anw110 kDa protein band
that specifically coimmunoprecipitated with
CTM-PC1 expressed in MDCK cells yielded
ten peptide sequences belonging to P100
(GenBank accession NM_014390) covering
10% of the sequence. Mo, oxidized methio-
nine.
(B) MDCK cells stably transfected for CTM-
PC1 or NTM-PC1 as a control were induced
with DOX for 16 hr or left uninduced. PC1 con-
structs were immunoprecipitated with an an-
tibody against CD16. P100 was detected by
Western blot with an antibody against a C-ter-
minal 16 kDa fragment. Note that P100 copre-
cipitates with CTM-PC1, but not NTM-PC1.
(C) GST and P100-GST fusion proteins were
immobilized on glutathione Sepharose and
incubated with the lysate of MDCK cells sta-
bly expressing CTM-PC1. Bound proteins
were analyzed by immunoblot for PC1 with
the aCT antibody.
(D) The expression levels of GST and GST-
P100 are shown by Coomassie staining in (ar-
rowheads indicate the full-length proteins).
(E) MDCK cells stably transfected for CTM-
PC1 were induced with DOX for 16 hr. P100
and CTM-PC1 were detected by confocal im-
munofluorescencemicroscopy. Thefieldcon-
tains a cell that expresses CTM-PC1 (aster-
isk), while others do not. The arrowheads
highlight colocalization. The scale bar is 5 mm.fragment generated from full-length PC1 seen in
Figure 2B. The size difference is likely due to the addi-
tional C-terminal, highly negatively charged FLAG tag
of the latter. This result suggests that a cleavage site
in the middle of the cytoplasmic tail of PC1 can be rec-
ognized and cleaved independent of preceding parts
of the molecule.
Nuclear Localization Is Mediated by the C-Terminal
Half of the PC1 Tail
To verify that the C-terminal half of the PC1 tail is suffi-
cient for nuclear translocation, we tested three addi-
tional constructs (Figure 1A). As shown in Figure 2E,
NTS-PC1 mainly localizes to the cytoplasm, whereas
both CTS-PC1 and CTSP-PC1 prominently localize to
the nucleus in transfected cells. The observed expres-
sion levels were consistently lower for CTSP-PC1 than
for CTS-PC1, suggesting that the PEST sequence con-
tained in CTSP-PC1 indeed promotes proteasomal deg-
radation. CTS-PC1 appeared to be less concentrated in
the nucleus compared to CTSP-PC1. However, treat-
ment with leptomycin B, an inhibitor of nuclear export,
resulted in strong nuclear accumulation of CTS-PC1
(Figure 3), suggesting that its initially lower relative nu-
clear accumulation was due to a saturation effect
caused by the higher expression level. These results in-
dicate that nuclear localization is mediated by the C-ter-
minal half of the PC1 tail and suggest that the PC1 tail
undergoes nuclear shuttling.
The PC1 Tail Binds to P100
These observations suggested that the cleaved PC1 tail
may have a signaling function and may regulate tran-scription in the nucleus. In order to identify interacting
proteins that may mediate this function, we isolated
binding proteins by coimmunoprecipitation and protein
sequencing by mass spectrometry. CTM-PC1 was ex-
pressed in MDCK cells for 16 hr and was immunoprecip-
itated. Uninduced cells served as negative controls.
SDS-PAGE revealed several proteins that specifically
bound to CTM-PC1 (data not shown) and were identified
by mass spectrometry. A band ofw110 kDa yielded ten
peptide identifications belonging to the protein EBNA2
coactivator, also known as P100 (Figure 3A). Immuno-
blotting with an antibody against P100 verified this iden-
tification and showed that P100 coprecipitates with
CTM-PC1, but not with NTM-PC1 (Figure 3B). The
same band also reacts with an antibody against a differ-
ent domain of P100 (data not shown). P100 is a ubiqui-
tously expressed transcription factor that was originally
identified as a coactivator of the Epstein Barr virus nu-
clear antigen 2 (Tong et al., 1995).
Next, we generated a recombinant P100-GST fusion
protein (Figure 3D) and used it in pull-down experiments
with total cell lysates from MDCK cells expressing CTM-
PC1 under DOX control. As shown in Figure 3C, CTM-
PC1 interacts with P100-GST, but not with GST alone.
This confirms the interaction between the PC1 tail and
P100 and suggests that it is direct.
As a further test, CTM-PC1 was expressed in subcon-
fluent MDCK cells in which it localizes prominently to the
endoplasmic reticulum (Figure 3E). In nontransfected
MDCK cells, P100 localizes mainly to the nucleus and
diffusely in the cytoplasm. However, in cells that express
CTM-PC1 (asterisk), a significant fraction of P100 is re-
targeted and partially colocalizes with CTM-PC1 (arrow-
heads), confirming the interaction in vivo. Altogether,
Polycystin-1/STAT6/P100 Signaling Pathway
61Figure 4. P100 Partially Localizes to Basal
Bodies and Cilia and Is Overexpressed in
ADPKD
(A–C) MDCK cells were cultured on a filter
support for 13 days. P100 (green) and acety-
lated tubulin (red), a cilia marker, were de-
tected by immunofluorescence microscopy.
Shown are projections of confocal optical
sections of the apical region of the cells. In
addition to nuclear and cytoplasmic staining
(data not shown), P100 localizes to the basal
bodies underneath the cilia, with a smaller
fraction penetrating into the cilia shafts (ar-
rowheads). The scale bar is 5 mm.
(D and E) Immunohistochemistry for P100 in
(D) normal human kidney and (E) ADPKD kid-
ney. Histological counterstaining was omit-
ted. For comparison, the immunohistochem-
istry was carried out side by side, and images
were acquired under identical conditions.
The scale bar is 20 mm.these experiments establish that P100 interacts with the
C-terminal half of the tail of PC1.
P100 Partially Localizes to the Basal Body
and Primary Cilia in Polarized MDCK Cells
and Is Overexpressed in ADPKD
P100 has been reported to localize to the nucleoplasm
and to cytoplasmic membrane organelles (Broadhurst
and Wheeler, 2001; Tong et al., 1995). As shown in
Figure 3E, a large fraction of P100 localizes to the nu-
cleus in subconfluent, nonpolarized MDCK cells. To in-
vestigate the localization of P100 in fully polarized cells,
MDCK cells were cultured on permeable filter supports
for 13 days, during which they develop apical primary
cilia. Confocal immunofluorescence microscopy with
two antibodies against different domains of P100 re-
vealed identical results. In addition to diffuse cytoplas-
mic and nucleoplasmic staining, a significant fraction
of P100 localizes to the basal body from which primary
cilia originate, and a minor fraction localizes to the cilia
shafts (Figure 4C). PC1 has also been shown to localize
to the cilia and the basal bodies of renal epithelial cells
(Nauli et al., 2003; Yoder et al., 2002). Therefore, our lo-
calization and binding data suggest that a fraction of
P100 may exist in a constitutive complex with PC1 on
the basal bodies and cilia.
Next, we investigated the expression and localization
of P100 in the kidney. As shown in Figure 4D, P100 is ex-
pressed in renal epithelial cells and exhibits predomi-
nantly nuclear localization in normal human kidney. In
ADPKD renal tissue, P100 is overexpressed in the
cyst-lining epithelial cells (Figure 4E), which was consis-
tent among all specimens tested. Virtually all cysts ex-
hibited a strong nuclear and cytoplasmic P100 immuno-
signal, suggesting that the transcriptional activity of
P100 is abnormally high in cystic cells. Two different
P100 antibodies against different regions of the mole-
cule and another antibody against full-length P100-
GST yielded identical results (data not shown).The PC1 Tail Binds to STAT6 and Stimulates
STAT6-Dependent Transcription
Our findings of an interaction between P100 and PC1,
and their colocalization at cilia, suggested the possibility
that P100 could be involved cilia-mediated mechano-
sensation. P100 has been shown to bind to the tran-
scription activation domain of STAT6, and to enhance
interleukin-4 (IL-4)-induced activation of Ig3 transcrip-
tion in human B cells (Yang et al., 2002). P100 appears
to function as a bridging protein between the sequence-
specific transcription factor STAT6 and the basal tran-
scription machinery (Tong et al., 1995; Yang et al., 2002).
To test whether STAT6 may participate in a signaling
pathway involving PC1 and P100, we investigated their
potential binding interactions. MDCK cells stably trans-
fected for FLS-PC1 under DOX control were treated with
IL-4 or were left untreated, lysed, and subjected to im-
munoprecipitation with an antibody against STAT6.
Figure 5A shows that MDCK cells express endogenous
STAT6 and activate it by tyrosine phosphorylation in re-
sponse to IL-4 treatment. STAT6 specifically precipi-
tates with FLS-PC1 in a DOX-dependent fashion. IL-4
had no apparent effect on the binding to FLS-PC1. En-
dogenous P100 also coprecipitates with STAT6, and
this interaction is also independent of IL-4 (Figure 5A),
as previously reported (Yang et al., 2002). These results
indicate that the PC1 tail interacts with STAT6, possibly
via P100. Neither binding of P100 nor of the PC1 tail re-
quires tyrosine phosphorylation of STAT6, suggesting
that these proteins exist in a constitutive complex.
Next, we tested whether the PC1 tail can regulate
STAT6-dependent transcription by using a luciferase re-
porter construct containing five copies of a STAT6 bind-
ing element (Haque et al., 1997). Stimulation with a low
concentration of IL-4 increases STAT6-dependent lucif-
erase activity 5-fold, as expected (Figure 5B). Coexpres-
sion of the FLS-PC1, CTSP-PC1, or CTS-PC1 con-
structs all resulted in a significant further stimulation of
STAT6 activity, whereas the NTS-PC1 construct had
Developmental Cell
62Figure 5. The C-Terminal Half of the PC1 Tail
Interacts with STAT6 and Activates STAT6-
Dependent Transcription
(A) MDCK cells stably transfected for FLS-
PC1 were cultured overnight with ALLN
(10 mM) in the presence or absence of DOX
(50 ng/ml). Cells were treated with 20 ng/ml
canine IL-4 for 30 min where indicated and
were lysed for immunoprecipitation with
anti-STAT6. Binding proteins were detected
with the indicated antibodies. The asterisk
denotes the rabbit Ig heavy chain.
(B–G) HEK293T cells were transfected with
luciferase reporter constructs containing
either (B–E) STAT6, (F) wnt-, or (G) AP-1-
responsive promotors along with the indi-
cated PC1 constructs. Reporter assays were
carried out 36 hr after transfection. Cells were
treated with the indicated concentrations of
(C) IL-4 or with (B, D, and E) 0.4 ng/ml IL-4.
(F) The wnt reporter contains tandem repeats
of TCF/LEF enhancer elements or mutated,
inactive elements (TOP- and FOP-FLASH, re-
spectively). Relative luciferase activity repre-
sents luciferase units normalized with b-gal
activity. Bars + SD are the average of normal-
ized luciferase units from three wells of a 12-
well plate, and all experiments were repeated
at least three times.no significant effect. At all concentrations of IL-4 tested,
FLS-PC1 further stimulates STAT6 activity (Figure 5C);
however, the relative effect is greatest at low IL-4 con-
centrations. The PC1 tail constructs also stimulate the
basal transcriptional activity of STAT6 in the absence
of IL-4 by approximately 2-fold (Figure 5B). These re-
sults indicate that the C-terminal half of the cytoplasmic
tail of PC1 positively regulates STAT6-dependent tran-
scription.
The membrane-anchored PC1 tail (FLS-PC1) does not
result in any increase in luciferase activity (Figure 5D),
which further suggests that the PC1 tail indeed has
to travel to the nucleus to affect STAT6-dependent tran-
scription. We consistently observed a decrease of IL-4-
stimulated STAT6 activity upon expression of FLM-PC1
(Figure 5D), which suggests that the membrane-
anchored PC1 tail has a dominant-negative function,
presumably by membrane sequestration of STAT6
and/or P100.
We mutated two aspartate residues in the PEST mo-
tifs of CTSP- and FLS-PC1. As shown in Figure 5B, these
DD/AA mutants exhibit increased stimulation of
STAT6 activity. This suggests that the stimulatory activ-ity of the PC1 tail is regulated by its degradation, which
is mediated by the PEST motif.
Canonical STAT6 activation requires phosphorylation
of a critical tyrosine residue (Y641). As shown in Fig-
ure 5E, no STAT6-dependent luciferase activity is ob-
served with the Y641F mutant, irrespective of the pres-
ence of the PC1 tail, indicating that the regulation by
the PC1 tail depends on tyrosine phosphorylation of
STAT6.
Altogether, these results show that the C-terminal half
of the PC1 tail is capable of interacting with P100 and
STAT6, which leads to an enhancement of STAT6-de-
pendent transcription both under basal conditions and
after IL-4 induction. The PEST domain in the PC1 tail ap-
pears to function in its downregulation.
It has previously been reported that expression of the
membrane-anchored constructs FLM-PC1 and CTM-
PC1 in transiently transfected HEK293 cells causes acti-
vation of the wnt signaling pathway via stabilization of b-
catenin (Kim et al., 1999b). To test whether this effect
may also involve cleaved, soluble fragments of the
PC1 tail, we used luciferase reporters containing tan-
dem repeats of TCF/LEF enhancer elements or mutated
Polycystin-1/STAT6/P100 Signaling Pathway
63Figure 6. STAT6 Localizes to Cilia and Trans-
locates to the Nucleus under ‘‘No-Flow’’ Con-
ditions
(A–D) MDCK cells were cultured for 13 days on
filter supports. Cells were then subjected to (C
and D) orbital shaking at 1 Hz for 16 hr to
mimic lumenal fluid flow or were (A and B)
left unshaken. STAT6 (green) and tubulin
(red) were detected by confocal immunofluo-
rescence microscopy. The panels in (A) and
(C) are projections of optical sections of the
apical regions of the cells, whereas panels in
(B) and (D) are projections of the nuclear re-
gions of the same fields. The scale bar is 5 mm.
(E and F) MDCK cells were transiently trans-
fected for V5-tagged STAT6 and were cul-
tured for 24 hr on filter supports. Cells in (F)
were subsequently shaken for 16 hr at 1 Hz,
whereas cells in (E) were left unshaken. The
confocal X-Z sections show immunostaining
for acetylated tubulin (red), STAT6 (green),
and nuclear DAPI staining (blue).
(G and H) MDCK cells were cultured and sub-
jected to apical fluid flow as in (C) and (D).
Cells were treated for 16 hr with (H) canine
IL-4 or were (G) left untreated and stained
for STAT6.
(I and J) Immunohistochemical detection of
STAT6 in (J) ADPKD kidney or (I) normal hu-
man kidney. The scale bar is 20 mm.
(K–P) Analysis of mouse kidney. The kidney in
(K), (M), and (O) was rapidly perfused with fix-
ative, whereas the kidney in (L), (N), and (P)
was fixed by immersion fixation. (K) and (L)
are stained for STAT6. In (K), STAT6 is shown
prominently localizing to primary cilia (arrow-
heads), whereas in (L), it is shown localizing to
the nuclei. To detect primary cilia, the section
in (M) was stained with an antibody against
acetylated tubulin. (N) and (O) show negative
controls with omission of the primary anti-
body. (P) shows an H&E-stained section.
The scale bar is 10 mm.elements (TOP- and FOP-FLASH, respectively). Neither
the membrane-anchored nor any of the soluble PC1
constructs were able to stimulate b-catenin-dependent
transcription (Figure 5F). Identical results were obtained
by using a luciferase reporter construct containing the
wnt-responsive Siamois promoter (data not shown).
These results are consistent with a previous report of
failure to affect wnt signaling by similar membrane-an-
chored PC1 constructs (Le et al., 2004) and suggest
that PC1 and cleaved tail fragments may not be involved
in the regulation of wnt signaling.
The FLM-PC1 and NTM-PC1 constructs have been re-
ported to activate a signaling pathway resulting in in-
creased AP-1-dependent transcription in HEK293 cells
(Arnould et al., 1998). To test whether this may involve
soluble fragments of the PC1 tail, we used an AP-1-re-
sponsive luciferase reporter. As shown in Figure 5G,
the membrane-anchored FLM-PC1 and NTM-PC1 stim-
ulate AP-1 activity as previously reported. However, all
of the soluble PC1 tail constructs tested failed to stimu-
late AP-1 activity. These results indicate that not all sig-
naling events involving the C terminus of PC1 require
cleavage and nuclear translocation of the tail, and sug-
gest that this is a specific function of the STAT6/P100-
dependent pathway described here.STAT6 Localizes to Cilia in Polarized MDCK Cells
and Translocates to the Nucleus under
‘‘No-Flow’’ Conditions
The function of STAT6 in the immune system has been
extensively investigated (Ostrand-Rosenberg et al.,
2004). STAT6 is widely expressed in many other tissues,
including the kidney (Hou et al., 1994; Quelle et al., 1995),
but little is known about its function outside of the im-
mune system. We tested where STAT6 may localize in
polarized MDCK cells. Fully polarized MDCK cells ex-
hibited nuclear localization of STAT6, but no immuno-
signal was detectable at the basal body or the primary
cilia (Figures 6A and 6B). However, subjecting the cells
to a constant flow of fluid across the apical membrane
by culturing for 16 hr on an orbital shaker at 1 Hz caused
a dramatic shift in the localization of STAT6. As shown in
Figures 6C and 6D, a large fraction of STAT6 localizes to
the primary cilia under these conditions with virtually no
detectable nuclear signal. In order to ensure that the en-
dogenous immunosignals are due to STAT6, we tran-
siently transfected epitope-tagged STAT6 into MDCK
cells and observed its localization. The cilia localization
of transfected STAT6 responded exactly like endoge-
nous STAT6 to the absence or presence of apical fluid
flow (Figures 6E and 6F). Note that a large fraction of
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Causes Pronephric Cysts in Zebrafish Em-
bryos
(A and B) Morphology of (A) control embryos
and (B) embryos injected with 60 pg FLS-PC1
mRNA at 2 days postfertilization (dpf).
(C) Histology of a 2 dpf control embryo show-
ing the glomerulus (Glm) and pronephric
ducts (Pd).
(D) An FLS-PC1 mRNA-injected embryo show-
ing cystic dilation of pronephric tubules (as-
terisks) and the glomerulus.
(E) RT-PCR analysis for human PC1 mRNA
expression and b-actin in 3 dpf embryos.
Control embryos (lane C) or human PC1-in-
jected embryos (lane PC1) were analyzed
with RT-PCR primers that generate a 522 bp
product.transiently transfected STAT6 localizes to the cytoplasm
and nucleoplasm irregardless of apical fluid flow. This is
likely due to the high overexpression level, and it sug-
gests that primary cilia contain a limited and saturable
number of STAT6 binding sites.
Treatment of ‘‘no-flow’’ MDCK cells with IL-4 for
30 min had no effect on STAT6 localization (data not
shown). However, treatment of ‘‘flow’’ MDCK cells with
IL-4 resulted in the loss of localization of STAT6 on cilia
(Figures 6G and 6H), suggesting that tyrosine phosphor-
ylation of STAT6 alone is sufficient for its translocation.
Together, these results suggest that STAT6 is in-
volved in the transduction of a mechanical signal that
originates at the primary cilia, and that this signal is ac-
tivated under ‘‘no-flow’’ conditions.
Investigation of the expression and localization of
STAT6 in human kidney revealed that STAT6 is moder-
ately expressed in renal epithelial cells of normal control
kidney (Figure 6I). In contrast, STAT6 is overexpressed
in cyst-lining epithelial cells in ADPKD kidneys (Fig-
ure 6J), which was consistent among virtually all cysts
in all patient specimens tested.
Since our available human ‘‘control’’ renal tissue
specimens are normal adjacent tissues derived from ne-
phrectomies due to renal tumors, the time lapse from the
clamping of the renal artery during nephrectomy (which
will halt renal tubular fluid flow) to the fixation of the tis-
sue usually exceeds 1 hr. Furthermore, immersion fixa-
tion requires several hours to take full effect. Our
above-described results with MDCK cells suggested
that, under these conditions, STAT6 may have translo-
cated from primary cilia to nuclei. In order to test
whether the ciliary localization of STAT6 can be de-
tected in rapidly fixed tissue, we perfused fixed mouse
kidneys directly via the renal arteries. Surgical time
was minimized to less than 3 min. Under these condi-
tions, STAT6 is clearly detectable on primary cilia of re-
nal epithelial cells (Figure 6K). In contrast, mouse kid-
neys fixed by conventional slow immersion fixation
predominantly exhibited nuclear localization of STAT6
(Figure 6L) similar to human tissue (Figure 6I). Together,
these results demonstrate that STAT6 translocates from
primary cilia to the nuclei of renal epithelial cells in vitro
and in vivo in response to the cessation of apical/
lumenal fluid flow. Cysts in ADPKD kidneys exhibit
very high nuclear expression of STAT6, indicating thatSTAT6-dependent gene expression is highly upregu-
lated in ADPKD.
Expression of the PC1 Tail Causes Renal Cyst
Formation in Zebrafish
We tested whether overexpression of the soluble PC1
tail alone may promote renal cyst formation. Zebrafish
have been used extensively in the past as a model sys-
tem by which to study renal cystogenesis (Drummond,
2005). Zebrafish embryos were injected at the one-cell
stage with mRNA encoding the human PC1 tail (FLS-
PC1). Control injected embryos show no morphological
abnormalities during embryonic development (Figures
7A and 7C). In contrast, pronephric kidney cysts were
observed histologically in PC1 tail mRNA-injected em-
bryos examined at 2 days postfertilization (dpf) (Fig-
ure 7D). The pronephric kidney is the functional kidney
of zebrafish embryos and larvae (Drummond et al.,
1998). At 3 dpf, renal cysts and liver cysts were visible
in 1098 (90%) of a total of 1220 injected embryos. This
result indicates that exogenous overexpression of the
soluble PC1 tail alone can recapitulate renal cyst forma-
tion in this model system.
Discussion
We demonstrate here a novel, to our knowledge, signal-
ing mechanism by which PC1 regulates STAT6-depen-
dent transcription. This involves cleavage of the cyto-
plasmic tail of PC1, which releases the C-terminal half
of the tail from the membrane. This fragment binds to
STAT6 and the transcriptional coactivator P100, translo-
cates to the nucleus, and activates STAT6-dependent
transcription. The finding that STAT6 translocates from
cilia to nuclei in the absence of apical fluid flow makes
it highly likely that this PC1/STAT6/P100 pathway is in-
volved in the transduction of a mechanical signal to a
transcriptional response. This pathway appears to be
strongly upregulated in human ADPKD cysts, suggest-
ing that it plays an important role in the pathogenesis
of the human disease.
PC1 Tail Cleavage and Nuclear Translocation
Our finding of a nuclear immunosignal in renal epithelial
cells with antibodies against the PC1 tail (Figure 1) is con-
sistent with a recent report that demonstrated nuclear
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65PC1 in transgenic mice overexpressing PC1 (Chauvet
et al., 2004). To our knowledge, for the first time, we re-
port the nuclear localization of endogenous PC1 in hu-
man kidney and show that nuclear PC1 is highly upregu-
lated in human ADPKD, which suggests that it plays a
role in the disease process. Several investigators have
reported cytoplasmic or membrane staining for PC1 in
normal and ADPKD human kidney. While many of these
reports have been in disagreement with each other
with respect to the subcellular localization and cell type-
specific expression, no nuclear localization has been re-
ported (reviewed in Nauta et al., 2000). However, in many
of these studies, antibodies against regions of PC1 other
than the C-terminal tail were used with which no nuclear
signal would be expected. Furthermore, histological nu-
clear counterstaining used in most studies would likely
have obscured weak nuclear immunosignals. These are
likely reasons why the nuclear localization of the PC1
tail has not, to our knowledge, previously been recog-
nized.
The finding that the PC1 tail undergoes nuclear trans-
location after cleavage may place PC1 in a growing class
of signaling membrane proteins that undergo ‘‘regulated
intramembrane proteolysis’’ (RIP) (Urban and Freeman,
2002; Wolfe and Kopan, 2004). In most of these cases,
the membrane protein is subjected to two proteolytic
events. The first occurs in an extracytoplasmic domain
and is followed by cleavage in a transmembrane domain
that releases the cytoplasmic domain. It is intriguing that
extracytoplasmic proteolysis at a GPS domain of PC1
has also been reported (Qian et al., 2002). In analogy
to the situation, in most known cases of RIP, we specu-
late that GPS domain cleavage may precede the cleav-
age of the cytoplasmic tail.
Based on its molecular weight, we estimate that the
cleavage site within the PC1 tail lies immediately N-ter-
minal to the PEST sequence in the middle of the tail. In
most examples of RIP, however, cleavage occurs within
a transmembrane domain. We cannot exclude the possi-
bility that PC1 first undergoes cleavage at a transmem-
brane domain, and that this is then followed by a second-
ary cleavage event, possibly by a soluble cytosolic
protease. However, we observed that expression of the
FLM-PC1 fusion protein also results in the generation
of a fragment equivalent to the C-terminal half of the
tail (Figure 2C). Since the transmembrane domain of
FLM-PC1 is derived from a different protein (CD7), it ap-
pears unlikely that the same intramembrane proteolytic
event would occur with this fusion protein. We therefore
consider it more likely that the PC1 tail is cleaved by
a membrane-associated or cytoplasmic protease that
is not a typical RIP protease, but consists of a hydrophilic
catalytic domain and cleaves a sequence in the middle of
the tail. Chauvet et al. (2004) recently reported C-terminal
cleavage of PC1 leading to the generation of a 34 kDa
fragment that is considerably larger than the proteolytic
product that we report here, and would be predicted to
contain some of the last integral membrane domains of
PC1. Although this remains to be tested, we speculate
that this large fragment may be the product of a classical
RIP protease such as g-secretase. However, given the
likely presence of hydrophobic domains, it appears un-
likely that the 34 kDa fragment is the active component
that undergoes nuclear translocation.We show that the cleaved tail of PC1 is unstable and
can only be detected after inhibition of proteasomal
degradation. This is a common feature in most exam-
ples of RIP signaling (Urban and Freeman, 2002; Wolfe
and Kopan, 2004). Our results suggest that a PEST se-
quence in the middle of the PC1 tail contributes to its
rapid degradation. PEST domains are thought to mark
proteins for degradation by the ubiquitin-proteasome
pathway (Rechsteiner and Rogers, 1996). Interestingly,
Kim et al. (2004) recently identified Siah-1 as an interact-
ing protein to the C-terminal half of the PC1 tail and
could show that this RING finger motif protein promotes
the ubiquitin-dependent proteasomal degradation of
PC1. Our results indicate that the PC1 tail is highly over-
expressed in cyst-lining renal epithelial cells in ADPKD,
where it exhibits significant nuclear localization. We
therefore suggest that this phenotype may be caused ei-
ther by enhanced cleavage of PC1 or by inhibition of its
proteasomal degradation.
The Role of P100
P100 localizes to the basal body and primary cilia (Fig-
ure 4), and it interacts with the C-terminal half of the
PC1 tail (Figure 3). This suggests that P100 may exist
in a stable complex with PC1, which also partially local-
izes to cilia (Nauli et al., 2003; Yoder et al., 2002). P100
promotes cell growth (Tong et al., 1995). Given that we
observed high expression of P100 in cysts, this sug-
gests that it may be an important contributor to cyst for-
mation and growth in ADPKD. We did not observe signif-
icant flow-induced differences of P100 localization in
MDCK cells (data not shown). The reason for this may
be that the expression level of P100 is much higher
than that of STAT6 and PC1, and that P100 is likely to
have many functions besides the STAT6/PC1 function
described here. Interestingly, P100 has been shown to
be strongly upregulated in mammary epithelial cells dur-
ing lactation (Broadhurst and Wheeler, 2001). Under
these conditions, mammary epithelial cells proliferate
and undergo a differentiation program that results in
a highly secretory phenotype. It is intriguing that prolifer-
ation and a change to a secretory phenotype are also
hallmarks of affected renal epithelial cells in PKD.
The Role of STAT6
Expression of the PC1 tail resulted in stimulation of
STAT6-dependent transcription, even in the absence
of IL-4 stimulation. However, IL-4 treatment, which trig-
gers tyrosine phosphorylation and dimerization of
STAT6, strongly enhanced this effect. Furthermore, the
STAT6-Y641F mutant was not stimulated by the PC1
tail. These results indicate that tyrosine-phosphorylated
STAT6 is the active component in the PC1-regulated
signaling pathway.
STAT proteins are tyrosine phosphorylated by mem-
bers of the Janus kinase (JAK) family, tyrosine kinase
growth factor receptors, nonreceptor tyrosine kinases,
and seven transmembrane pass receptors (Calo et al.,
2003). Four members of the JAK family are known:
JAK1–3 and Tyk2. PC1 has previously been shown to
bind to JAK2, which was shown to lead to activation of
STAT1 (Bhunia et al., 2002). These authors did, however,
not detect binding to JAK1 or Tyk2; JAK3 was not
tested. In immune cells, STAT6 has been shown to be
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(A–D) See Discussion for a description.phosphorylated by JAK1 and JAK3, but not by JAK2.
While this remains to be established, we propose that
JAK3 may be involved in PC1-dependent activation of
STAT6. Alternatively, JAK2 may exhibit altered sub-
strate specificity when activated by PC1 and may be
able to phosphorylate STAT6. Either way, PC1 is clearly
a nonclassical activator of STAT function. Not only does
it bind to a Janus kinase and cause tyrosine phosphory-
lation of STAT proteins (Bhunia et al., 2002), but it is also
cleaved, and the resulting cytoplasmic fragment re-
mains bound to the STAT protein to affect transcription
in the nucleus as shown in this study. To our knowledge,
this is the first example of such a mechanism of STAT
activation.
Our results indicate that the function of the cleaved
PC1 tail is specific to STAT6 activation and does not af-
fect two other signaling pathways that have previously
been shown to be affected by membrane-anchored fu-
sion proteins containing the PC1 tail, namely, the wnt/
b-catenin pathway and the AP-1 pathway. A recent re-
port by Chauvet et al. (2004) appears to be inconsistent
with our finding that AP-1 is unaffected. These authors
report that a construct similar to our FLS-PC1 construct
stimulates the response of an AP-1-sensitive luciferase
reporter plasmid. However, Chauvet et al. (2004) did
not observe AP-1 stimulation with a membrane-an-
chored fusion protein of the PC1 tail, which is in contrast
to the results of three different groups (Arnould et al.,
1998; Kim et al., 1999b; Le et al., 2004; Parnell et al.,
2002) and to our findings (Figure 5G). Furthermore, Ar-
nould et al. (1998) have previously reported that AP-1 ac-
tivation depends on the membrane localization of the
PC1 tail and is completely lost with a soluble PC1 con-
struct that is similar to those used by us and Chauvet
et al. Finally, the domain of PC1 that affects AP-1 signal-
ing has been shown to be contained in the N-terminal
half of the tail (Kim et al., 1999b), whereas our results
show that the C-terminal half of the tail is released by
proteolysis. Further work may be required to clarify
this discrepancy.
Primary Cilia and Flow Sensing
We show that STAT6 is expressed in MDCK cells as well
as in renal epithelial cells in vivo. In both cases, STAT6
localizes to the primary cilia under conditions of fluid
flow across the apical plasma membrane. Mechanical
stimulation of primary cilia in renal epithelial cells results
in temporary elevation of cytosolic calcium (Nauli et al.,
2003; Praetorius and Spring, 2001). It is likely that renal
epithelial cells need to be able to respond quickly tochanging rates of fluid flow. Whereas a calcium re-
sponse is an ideal signal to affect fast and temporary
cellular responses, we propose that STAT6-mediated
signaling plays a role in a long-term response to
changes in renal fluid flow. Renal injury may create con-
ditions of ceased lumenal fluid flow, to which epithelial
cells need respond by initiating a repair program that
typically involves dedifferentiation and proliferation. In
renal cystic diseases, lumenal fluid flow is strongly de-
creased or absent in dilated tubules and cysts, respec-
tively. Our results suggest that, under these ‘‘no-flow’’
conditions, ciliary STAT6 will translocate to the nucleus
and affect gene expression. The nuclear expression of
STAT6, P100, and the cytoplasmic tail of PC1 are all
highly elevated in cystic epithelial cells of ADPKD pa-
tients, which suggests that these cells may be in a state
in which they inappropriately attempt to respond to
a ‘‘no-flow’’ condition, such as that caused by renal in-
jury. While the genes regulated by the PC1/STAT6/
P100 pathway still need to be identified, we speculate
that the activation of this pathway will trigger a prolifera-
tive response and a loss of differentiation, and that this
is an important factor in renal cyst formation.
Model and Relevance to ADPKD
A working model that is consistent with our data is
shown in Figure 8. Under normal flow conditions (Fig-
ure 8A), PC1 localizes to primary cilia, where it is in a
complex with P100 and STAT6. The normal function of
PC1 would be to sequester STAT6 and prevent the ex-
pression of STAT6/P100-dependent genes. This is sup-
ported by our finding that the membrane-anchored PC1
tail suppresses STAT6 activity (Figure 5D). This state re-
mains stable as long as the cilia remain bent by lumenal
fluid flow. Renal injury resulting in cessation of fluid flow
(Figure 8B) will trigger cleavage of the cytoplasmic tail of
PC1 by a yet unknown mechanism and protease. This is
accompanied by STAT6 tyrosine phosphorylation, nu-
clear translocation of the PC1 tail/STAT6/P100 complex,
and activation of gene expression.
We propose two scenarios that will lead to aberrant
STAT6 activity in ADPKD. If PC1 is completely lost
(e.g., due to a large gene deletion in both alleles, an un-
likely event), STAT6 cannot be sequestered at the cilia
and may be constitutively activated (Figure 8C). This
scenario should also apply to PKD1 knockout mouse
models. It is more commonly observed in ADPKD that
PC1 is actually highly expressed in cyst-lining epithelial
cells. However, overexpressed mutant PC1 may be mis-
folded and degraded. Degradation of PC1 may release
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terminal half of the tail. In this scenario (Figure 8D), not
only would STAT6 fail to be sequestered at the cilia,
but the PC1 tail would further increase STAT6-depen-
dent transcription. This scenario is consistent with our
finding of high levels of nuclear PC1 tail in ADPKD cysts.
Similarly, mutations in other genes whose products
are required for cilia formation or function may also in-
terfere with the inhibitory action of PC1 on STAT6 tran-
scription. Consistent with this model, the products of
most genes that have been identified in animal models
of renal cystic diseases have been shown to localize to
primary cilia (Delmas, 2004; Guay-Woodford, 2003;
Zhang et al., 2004).
Our model predicts that a loss of STAT6 function, per
se, may have little effect in a normal kidney. Indeed,
STAT6 null mice have been generated, and there has
been no report of any severe renal phenotype. Almost
the entire research effort to elucidate STAT6 function
has been focused on the immune system despite the
fact that this protein is widely expressed, including in
the kidney, as demonstrated previously by Northern
blot analysis (Hou et al., 1994) and as shown in this study.
It is striking that expression of the soluble PC1 tail
alone results in renal cyst formation in zebrafish. This
suggests that the function of the soluble PC1 tail is highly
conserved in evolution. Zebrafish have proteins closely
related to human P100 (Broadhurst et al., 2005) and
STAT6 (our unpublished data), but it remains to be inves-
tigated whether they function in a common pathway.
Overall, our results suggest that the PC1/STAT6/P100
signaling pathway described here plays an important
role in the cellular response to tubular fluid flow, and
that it is an important regulator of renal cyst formation
in ADPKD. Components of this pathway may be promis-




cDNAs of membrane-anchored PC1 constructs were gifts from Gerd
Walz (University Hospital Freiburg) and were cloned into pCDNA4/
TO (Invitrogen). All other PC1 constructs were made by PCR and
cloning into pCDNA4/TO-myc-His (Invitrogen). Two aspartate resi-
dues in the PEST sequence (residues 4173 and 4182) were replaced
by alanines in CTSP- and FLS-PC1. FLAG-tagged PC1 was provided
by Gregory Germino (Johns Hopkins University). A STAT6-luciferase
reporter containing five copies of a STAT6 binding element (N6-GAS)
(Haque et al., 1997) and plasmids encoding human STAT6 and V5-
tagged STAT6 were provided by Saikh Jaharul Haque and Pankaj
Sharma (Cleveland Clinic). A luciferase reporter containing AP-1 re-
sponse elements (TGACTAA)7 was obtained from Stratagene. A con-
stitutively active HA-tagged b-catenin (S37A) mutant and Siamois
promoter-Luciferase constructs were gifts from Catherine Mao (Uni-
versity of Kentucky) and Randall Moon (University of Washington),
respectively. TOP- and FOP-FLASH reporter plasmids were pro-
vided by Philip Howe and Barbara Hocevar (Cleveland Clinic).
Antibodies
Rabbit polyclonal antibodies (aFL and aCT) against the PC1 tail were
generated against GST fusion proteins corresponding to the FLS or
CTS constructs. Antibodies were affinity purified by using the anti-
gen cleaved from GST by thrombin and were immobilized on Affigel
(BioRad). Polyclonal antibodies against a C-terminal 16 kDa frag-
ment or an N-terminal 43 kDa fragment of P100 (Broadhurst and
Wheeler, 2001) were provided by Tom Wheeler (AgResearch, Ham-
ilton, New Zealand). An additional polyclonal rabbit P100 antibodywas generated by using a full-length P100-GST fusion protein as de-
scribed above.
Luciferase Assays
A total of 106 HEK293T cells were cultured overnight in six-well
plates to 80% confluency and were transfected with 3 mg luciferase
reporter and 150 ng b-galactosidase plasmid per well by using Lip-
ofectamine2000 (Invitrogen). Four hours posttransfection an equal
volume of media containing 20% FBS was added. After 16–18 hr,
cells were spilt into 12-well plates, and 6 hr later, they were induced
with IL-4 (R&D Systems). GFP in pCDNA4/TO was used for balancing
the plasmids in all transfections. Luciferase assays were carried out
after 16 hr of treatment with IL-4 with luciferase substrate (Promega),
and b-gal was detected by using ONPG in sodium phosphate buffer.
Immunofluorescence
MDCK cells were allowed to polarize by plating 0.5 million cells onto
Transwell filters, and cells were grown for 10–13 days. Prior to immu-
nofluorescence staining, cells were rotated on an orbital shaker
overnight at 1 Hz as described previously (Kolb et al., 2004). Nonpo-
larized MDCK cells for transfection were plated on coverslips and
were transfected while in suspension and incubated overnight be-
fore staining. Immunostaining was carried out as described previ-
ously (Weimbs et al., 2003).
Immunoprecipitation
Cells were washed in cold PBS and scraped with lysis buffer (50 mM
HEPES KOH [pH 7.4], 50 mM K-acetate, and 1% Triton X-100) con-
taining protease inhibitor cocktail, phosphatase inhibitors, and
0.5% BSA, and they were rotated for 30 min at 4ºC. Precleared ly-
sates were used for immunoprecipitation with anti-STAT6 antibody
(Santa Cruz, Inc., CA) overnight at 4ºC and were subsequently pulled
down by using protein A Sepharose beads for 1 hr at 4ºC. The beads
were washed with lysis buffer three times. Samples were analyzed
by Western blotting with the indicated antibodies.
Cell Fractionation
MDCK cells cultured on 10 cm dishes were rinsed with ice-cold PBS,
were scraped into 0.5 ml hypotonic buffer (20 mM HEPES, 5 mM
EDTA, protease inhibitors), and were passed through a 25 gauge
needle to break the cells. A 1,000 3 g spin was performed for 2
min at 4ºC to pellet the nuclei, and the supernatant was spun at
16,000 3 g for 30 min at 4ºC to pellet the membranes. The fractions
were loaded onto SDS-PAGE gels, and a Western blot was per-
formed with the antibodies indicated in the figure legends.
Human Samples
Tissue samples from ADPKD patients and normal controls were
obtained at the Cleveland Clinic as per institutional guidelines.
Samples were fixed and embedded in paraffin for immunohisto-
chemistry.
Zebrafish Experiments
Wild-type AB zebrafish were maintained and raised as described
(Westerfield, 1993). Zebrafish embryos were kept at 28.5ºC in E3 so-
lution and were staged according to hours postfertilization (hpf).
Embryos were microinjected at the one-cell stage with 20–60 pg
capped mRNA encoding FLS-PC1. In vitro-transcribed mRNA was
synthesized by using a mMessage mMachine T7 kit (Ambion) and
was injected into 200 mM KCl, 0.1% phenol red. Nested PCR primers
were used to detect human PC1 to confirm the expression in the in-
jected zebrafish embryos. Amplification of b-actin was performed as
a positive control. Embryos were fixed in 1.5% glutaraldehyde, 1%
paraformaldehyde, 70 mM NaPO4 (pH 7.2), 3% sucrose overnight
at 4ºC and were embedded in JB-4 resin (Polysciences) and sec-
tioned at 3 mm with HM325 (Richard-Allan Scientific). Slides were
stained with Methylene Blue and Azure II as described before (Drum-
mond et al., 1998).
Identification of P100 as a PC1 Binding Protein
MDCK cells stably expressing the CTM-PC1 construct were cultured
to confluency on 10 cm dishes. The cells were untreated (control) or
induced with 50 ng/ml DOX for 16 hr. Cells were lysed in 50 mM
HEPES, 50 mM K-acetate, 2% Triton X-100, protease inhibitors.
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pled to anti-CD16 antibody (Becton Dickson, CA). The beads were
washed with the above-described buffer, and bound proteins were
analyzed by SDS-PAGE. Coomassie blue-stained, specific bands
were excised, washed with 50% ethanol/5% acetic acid, reduced
with DTT, alkylated with iodoacetamide, and digested with trypsin
(Kinter and Sherman, 2000). The digests were analyzed by capillary
column LC-tandem mass spectrometry on a ThermoFinnigan
LCQdeca ion trap system with a nanospray ion source. Mass spec-
tra and CID spectra were collected, and CID spectra were used to
search the NCBI nonredundant database. All matching spectra
were verified by manual interpretation.
GST-P100 Binding Assay
MDCK cells stably transfected with CTM-PC1 were uninduced or in-
duced with 50 ng/ml DOX for 16 hr. The cells were lysed in 50 mM
HEPES (pH 7.4), 150 mM K-acetate, 2 mM DTT, 2% TX-100, protease
inhibitors. Precleared lysates were incubated with GST or GST-P100
fusion proteins immobilized on glutathione Sepharose beads (Amer-
sham) for 4 hr at 4ºC. Beads were washed four times with lysis buffer,
and proteins were analyzed by SDS-PAGE and immunoblotting.
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